keyword
MENU ▼
Read by QxMD icon Read
search

Hpv vaccines and safety

keyword
https://www.readbyqxmd.com/read/29333935/association-between-human-papilloma-virus-hpv-vaccination-and-risk-of-multiple-sclerosis-a-systematic-review
#1
Angela Meggiolaro, Giuseppe Migliara, Giuseppe La Torre
INTRODUCTION: The vaccination against Humanpapilloma Virus (HPV) is an effective strategy to prevent high-risk HPV infection and subsequent cervical carcinogenesis. Although the safety profile has been ascertained, the relation with the development of central nervous system (CNS) autoimmune disorders (AD) appears still controversial. Multiple Sclerosis (MS) is the most common cause of chronic neurological impairment in young people, typically striking females. The main purpose of this review was to assess the association between HPV vaccination and MS...
January 15, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29316817/therapeutic-dna-vaccines-for-human-papillomavirus-and-associated-diseases
#2
Max A Cheng, Emily Farmer, Claire Huang, John Lin, Chien-Fu Hung, T-C Wu
Human papillomavirus (HPV) has long been recognized as the causative agent of cervical cancer. High-risk HPV types 16 and 18 alone, are responsible for over 70% of all cases of cervical cancers. More recently, HPV has been identified as an etiological factor for several other forms of cancers, including oropharyngeal, anogenital, and skin. Thus, the association of HPV with these malignancies creates opportunity for the control of these HPV lesions and HPV-associated malignancies through immunization. Strategies to prevent or to therapeutically treat HPV infections have been developed and are still pushing innovative boundaries...
January 9, 2018: Human Gene Therapy
https://www.readbyqxmd.com/read/29303710/vaccinations-in-adults-with-rheumatoid-arthritis-in-an-era-of-new-disease-modifying-anti-rheumatic-drugs
#3
REVIEW
Pier Luigi Meroni, Daniela Zavaglia, Corrado Girmenia
Patients with rheumatoid arthritis are at greater risk of infectious morbidity and mortality due to disease-related abnormalities and use of immunosuppressive medications. Vaccinations are recommended by international guidelines among infection control strategies, but vaccination rates are reported to be still suboptimal in both America and Europe. Furthermore, with the increasing number of immunomodulatory medications used in RA patients, safety and efficacy of vaccinations in RA patients on such therapies have been questioned...
December 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29280070/safety-of-human-papillomavirus-vaccines-an-updated-review
#4
REVIEW
Anastasia Phillips, Cyra Patel, Alexis Pillsbury, Julia Brotherton, Kristine Macartney
Human papillomavirus (HPV) vaccines are now included in immunisation programmes in 71 countries. Unfortunately, uptake has been impacted in some countries by reduced confidence in the safety of the HPV vaccine. In 2013, we published an extensive review demonstrating a reassuring safety profile for bivalent (2vHPV) and quadrivalent (4vHPV) vaccines. A nonavalent (9vHPV) vaccine is now available and HPV immunisation programmes have been extended to males in 11 countries. The aim of this updated narrative review was to examine the evidence on HPV vaccine safety, focusing on the 9vHPV vaccine, special populations and adverse events of special interest (AESI)...
December 26, 2017: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/29278613/immunogenicity-and-safety-of-the-quadrivalent-human-papillomavirus-vaccine-in-girls-living-with-hiv
#5
Jason Brophy, Ari Bitnun, Ariane Alimenti, Normand Lapointe, Lindy Samson, Stanley Read, Christos Karatzios, Simon Dobson, Erin Moses, Sandra Blitz, Nancy-Grace Lipsky, Gina Ogilvie, Sharon Walmsley, Janet Raboud, Deborah Money
We evaluated quadrivalent HPV (qHPV) vaccine seroresponses among 35 girls living with HIV (ages 9-13) and compared to data on girls without HIV, as part of a subgroup analysis. The qHPV vaccine was safe and well-tolerated. However, antibody response was significantly lower in girls living with HIV relative to girls without HIV. HIV virologic suppression predicted better antibody response. CLINICAL TRIAL REGISTRATION: .
December 22, 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/29258972/characteristics-of-articles-about-human-papillomavirus-vaccination-in-japanese-newspapers-time-series-analysis-study
#6
Nao Ueda, Ryoki Yokouchi, Taro Onoda, Atsushi Ogihara
BACKGROUND: Media coverage and reports have a major influence on individual vaccination and other health-related activities. People use the media to seek information and knowledge on health-related behaviors. They obtain health-related information from media such as television and newspapers, and they trust such information. While several studies have examined the relation between media coverage and individual health, there is a lack of studies that have analyzed media reports of health information...
December 19, 2017: JMIR Public Health and Surveillance
https://www.readbyqxmd.com/read/29211620/safety-profile-of-the-9-valent-human-papillomavirus-vaccine-assessment-in-prior-quadrivalent-hpv-vaccine-recipients-and-in-men-16-to-26%C3%A2-years-of-age
#7
E D Moreira, A R Giuliano, J de Hoon, O-E Iversen, E A Joura, J Restrepo, P Van Damme, C Vandermeulen, M C Ellison, A Krick, C Shields, B Heiles, A Luxembourg
A 9-valent HPV (9vHPV) vaccine has been developed to protect against HPV type 6/11/16/18/31/33/45/52/58-related infection and disease. Previous safety analyses from 7 clinical trials conducted in 9vHPV vaccine recipients 9-26 years of age, including comparisons of 9vHPV and quadrivalent HPV (qHPV) vaccines in girls and women 16-26 years of age, showed that the 9vHPV vaccine was generally well tolerated. Additional safety analyses were conducted to include the results of new clinical studies. The safety profile of the 9vHPV vaccine in prior qHPV vaccine recipients (n = 3756 from 1 randomized controlled trial and 2 open-label extension studies) and young men (n = 248 9vHPV and n = 248 qHPV vaccine recipients from 1 randomized controlled trial) was evaluated...
December 6, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29179869/overcoming-barriers-in-hpv-vaccination-and-screening-programs
#8
Alex Vorsters, Marc Arbyn, Marc Baay, Xavier Bosch, Silvia de Sanjosé, Sharon Hanley, Emilie Karafillakis, Pier Luigi Lopalco, Kevin G Pollock, Joanne Yarwood, Pierre Van Damme
The Human Papillomavirus Prevention and Control Board brought together experts to discuss optimizing HPV vaccination and screening programs. Board members reviewed the safety profile of licensed HPV vaccines based on clinical and post-marketing data, reaching a consensus that current safety data is reassuring. Successful vaccination programs used well-coordinated communication campaigns, integrating (social) media to spread awareness. Communication of evidence supporting vaccine effectiveness had beneficial effects on the perception of the vaccine...
December 2017: Papillomavirus Research
https://www.readbyqxmd.com/read/29174109/comparative-immunogenicity-and-safety-of-human-papillomavirus-hpv-16-18-as04-adjuvanted-vaccine-and-4vhpv-vaccine-administered-according-to-two-or-three-dose-schedules-in-girls-aged-9-14%C3%A2-years-results-to-month-36-from-a-randomized-trial
#9
Ting Fan Leung, Anthony Pak-Yin Liu, Fong Seng Lim, Franck Thollot, Helen May Lin Oh, Bee Wah Lee, Lars Rombo, Ngiap Chuan Tan, Roman Rouzier, Stéphanie De Simoni, Pemmaraju Suryakiran, Marjan Hezareh, Florence Thomas, Nicolas Folschweiller, Frank Struyf
This observer-blind study (clinicaltrials.gov NCT01462357) compared the immunogenicity and safety of two doses (2D) of the HPV-16/18 AS04-adjuvanted vaccine (2D of AS04-HPV-16/18) vs. two or three doses of the 4vHPV vaccine [2D or 3D of 4vHPV] in 1075 healthy girls aged 9-14 years. Girls were randomized (1:1:1) to receive 2D of AS04-HPV-16/18 at months (M) 0, 6 (N = 359), 2D of 4vHPV at M0, 6 (N = 358) or 3D of 4vHPV at M0, 2, 6 (N = 358). 351, 339 and 346 girls, respectively, returned for the concluding visit at M36...
November 23, 2017: Vaccine
https://www.readbyqxmd.com/read/29161198/a-systematic-review-of-factors-influencing-human-papillomavirus-vaccination-among-immigrant-parents-in-the-united-states
#10
Kyounghae Kim, Anna-Rae LeClaire
To critically appraise factors influencing human papillomavirus (HPV) vaccination among immigrant parents in the United States, a comprehensive search of electronic databases and reference lists was conducted. The findings from 22 articles were ordered based on a socio-ecological model. About 30% of children initiated and 14% completed a 3-dose series. Correlates of HPV vaccine initiation rates included lack of information, concerns about vaccine safety and promiscuity, providers' recommendations, school mandates, financial issues, immigration laws, and living in disadvantaged neighborhoods...
November 21, 2017: Health Care for Women International
https://www.readbyqxmd.com/read/29157955/development-of-a-goat-model-for-evaluation-of-withaferin-a-cervical-implants-for-the-treatment-of-cervical-intraepithelial-neoplasia
#11
Leslie C Sherwood, Farrukh Aqil, Manicka V Vadhanam, Jeyaprakash Jeyabalan, Radha Munagala, David Hoetker, Sanjay Srivastava, Inder P Singh, Scott Cambron, Martin O'Toole, Wendy Spencer, Lynn P Parker, Ramesh C Gupta
Cervical cancer is caused by human papillomavirus (HPV). The disease develops over many years through a series of precancerous lesions. Cervical cancer can be prevented by HPV-vaccination, screening and treatment of precancer before development of cervical cancer. The treatment of high-grade cervical dysplasia (CIN(2+)) has traditionally been by cervical conization. Surgical procedures are associated with increased risk of undesirable side effects including bleeding, infection, scarring (stenosis), infertility and complications in later pregnancies...
November 17, 2017: Experimental and Molecular Pathology
https://www.readbyqxmd.com/read/29098504/examining-hpv-and-hpv-vaccine-related-cognitions-and-acceptability-among-us-born-and-immigrant-hispanics-and-us-born-and-immigrant-non-hispanic-blacks-a-preliminary-catchment-area-study
#12
Kimlin Tam Ashing, Agatha Carrington, Camille Ragin, Veronica Roach
PURPOSE: Disparities in HPV vaccination exist. Therefore, we investigated the distinction and disparities in HPV- and HPV vaccine-related cognitions and acceptability among US-born African Americans (AA) and Black immigrants, and between US-born Latinas and Latina immigrants. METHODS: Secondary data analyses were conducted with 383 female adults divided into non-Hispanic Blacks-(1) AA born in the US (n = 129) and (2) Black immigrants (n = 53), and Hispanics-(3) Latinas born in the US (n = 57) and (4) Latina immigrants (n = 144)...
November 2017: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/29080142/correction-to-safety-concerns-with-hpv-vaccines-continue-to-linger-are-current-vaccine-pharmacovigilance-practices-sufficient
#13
Rebecca E Chandler
The following disclaimer was missing from the article.
October 28, 2017: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/29074192/ipvs-policy-statement-on-safety-of-hpv-vaccines
#14
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Papillomavirus Research
https://www.readbyqxmd.com/read/29061232/reports-of-postural-orthostatic-tachycardia-syndrome-after-human-papillomavirus-vaccination-in-the-vaccine-adverse-event-reporting-system
#15
Jorge Arana, Adamma Mba-Jonas, Christopher Jankosky, Paige Lewis, Pedro L Moro, Tom T Shimabukuro, Maria Cano
PURPOSE: Human papillomavirus (HPV) vaccination prevents infections with HPV strains that cause certain cancers. Reports of postural orthostatic tachycardia syndrome (POTS) following HPV vaccination have raised safety concerns. We reviewed POTS reports submitted to the Vaccine Adverse Event Reporting System (VAERS). METHODS: We searched the VAERS database for reports of POTS following any type of HPV vaccination (bivalent, quadrivalent, or nonavalent) from June 2006 to August 2015...
November 2017: Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine
https://www.readbyqxmd.com/read/29044769/human-papillomavirus-vaccination-of-adult-women-and-risk-of-autoimmune-and-neurological-diseases
#16
A Hviid, H Svanström, N M Scheller, O Grönlund, B Pasternak, L Arnheim-Dahlström
BACKGROUND: Since 2006, human papillomavirus (HPV) vaccines have been introduced in many countries worldwide. Whilst safety studies have been reassuring, focus has been on the primary target group, the young adolescent girls. However, it is also important to evaluate safety in adult women where background disease rates and safety issues could differ significantly. OBJECTIVE: We took advantage of the unique Danish and Swedish nationwide healthcare registers to conduct a cohort study comparing incidence rate ratios (RRs) of 45 preselected serious chronic diseases in quadrivalent HPV (qHPV)-vaccinated and qHPV-unvaccinated adult women 18-44 years of age...
October 18, 2017: Journal of Internal Medicine
https://www.readbyqxmd.com/read/28986659/hpv-vaccination-in-japan-results-of-a-3-year-follow-up-survey-of-obstetricians-and-gynecologists-regarding-their-opinions-toward-the-vaccine
#17
Masaaki Sawada, Yutaka Ueda, Asami Yagi, Akiko Morimoto, Ruriko Nakae, Reisa Kakubari, Hazuki Abe, Tomomi Egawa-Takata, Tadashi Iwamiya, Shinya Matsuzaki, Eiji Kobayashi, Kiyoshi Yoshino, Tadashi Kimura
BACKGROUND: In Japan, the cervical cancer preventative HPV vaccination rate has dramatically declined, directly as a result of repeated broadcasts of so-called adverse events and the resulting suspension of the government's recommendation. Our previous survey of obstetricians and gynecologists in Japan regarding their opinions toward HPV vaccination revealed that these key specialists were as negatively influenced by the reports of purported negative events as were the general population...
October 6, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28986092/population-based-hpv-vaccination-programmes-are-safe-and-effective-2017-update-and-the-impetus-for-achieving-better-global-coverage
#18
REVIEW
Julia M L Brotherton, Paul N Bloem
Persistent oncogenic human papillomavirus (HPV) is the cause of cervical cancer, as well as cancers of the anus, penis, vulva, vagina and oropharynx. There is good evidence that prophylactic HPV vaccines are immunogenic and effective against targeted-type HPV infections and type-specific genital lesions, including high-grade cervical intraepithelial neoplasia (CIN), when administered prior to HPV infection. There is good evidence that HPV vaccines are safe in population usage, with the most frequent adverse event being injection-site reactions...
September 6, 2017: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/28984053/ten-year-immune-persistence-and-safety-of-the-hpv-16-18-as04-adjuvanted-vaccine-in-females-vaccinated-at-15-55%C3%A2-years-of-age
#19
Tino F Schwarz, Andrzej Galaj, Marek Spaczynski, Jacek Wysocki, Andreas M Kaufmann, Sylviane Poncelet, Pemmaraju V Suryakiran, Nicolas Folschweiller, Florence Thomas, Lan Lin, Frank Struyf
Women remain at risk of human papillomavirus (HPV) infection for most of their lives. The duration of protection against HPV-16/18 from prophylactic vaccination remains unknown. We investigated the 10-year immune response and long-term safety profile of the HPV-16/18 AS04-adjuvanted vaccine (AS04-HPV-16/18 vaccine) in females aged between 15 and 55 years at first vaccination. Females who received primary vaccination with three doses of AS04-HPV-16/18 vaccine in the primary phase-III study (NCT00196937) were invited to attend annual evaluations for long-term immunogenicity and safety...
November 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28970457/pharmacists-attitudes-and-perceived-barriers-to-human-papillomavirus-hpv-vaccination-services
#20
Tessa J Hastings, Lindsey A Hohmann, Stuart J McFarland, Benjamin S Teeter, Salisa C Westrick
Use of non-traditional settings such as community pharmacies has been suggested to increase human papillomavirus (HPV) vaccination uptake and completion rates. The objectives of this study were to explore HPV vaccination services and strategies employed by pharmacies to increase HPV vaccine uptake, pharmacists' attitudes towards the HPV vaccine, and pharmacists' perceived barriers to providing HPV vaccination services in community pharmacies. A pre-piloted mail survey was sent to 350 randomly selected community pharmacies in Alabama in 2014...
August 7, 2017: Pharmacy (Basel, Switzerland)
keyword
keyword
113339
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"